Bayer Adds Up COVID-19 Pluses and Minuses In Q1
Stockpiling Boost For Xarelto
Executive Summary
Bayer has beaten analyst forecasts for the first quarter but says the uncertainties brought about by the coronavirus pandemic prevent it from issuing financial guidance for the full year.